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322Objective: Thoracic endovascular aortic repair for chronic type B aortic dissection with associated descending
thoracic aneurysm remains controversial. Concerns include potential ischemic complications due to branch ves-
sel origin from the chronic false lumen and continued retrograde false lumen/aneurysm sac pressurization via
fenestrations distal to implanted endografts. The present study examines midterm results with thoracic endovas-
cular aortic repair for chronic (>2 weeks) type B aortic dissection with associated aneurysm to better understand
the potential role of thoracic endovascular aortic repair for this condition.
Methods: Between March 2005 and December 2009, 51 thoracic endovascular aortic repair procedures were
performed at a single institution for management of chronic type B dissection. The indication for thoracic en-
dovascular aortic repair was aneurysm in all cases. A subset of 7 patients (14%) underwent placement of the
EndoSure wireless pressure measurement system (CardioMEMS, Inc, Atlanta, Ga) in the false lumen adjacent
to the primary tear for monitoring aneurysm sac/false lumen pulse pressure after thoracic endovascular aortic
repair.
Results:Mean patient age was 57 12 years (range, 30–82 years); 14 patients (28%) were female. Mean aortic
diameter was 6.2  1.4 cm. There were no in-hospital/30-day deaths, strokes, or permanent paraplegia/paresis.
There were no complications related to compromise of downstream branch vessels arising from the false lumen.
Two patients (3.9%) who had preexisting ascending aortic dilation had retrograde acute type A aortic dissection;
both were repaired successfully. Median postoperative length of stay was 4 days. Mean follow-up is 27.0  16.5
months (range, 2–60months). Actuarial overall survival is 77.7% at 60months with an actuarial aorta-specific sur-
vival of 98% over this same time period. Actuarial freedom from reintervention is 77.3% at 60months. All patients
with the EndoSure wireless pressure measurement system exhibited a decrease in aneurysm sac/false lumen pulse
pressure indicating a depressurized false lumen. The aneurysm sac/false lumen pulse pressure ratio decreased from
52%  27% at the predischarge measurement to 14%  5% at the latest follow-up reading (P ¼ .029).
Conclusions: Thoracic endovascular aortic repair for chronic type B dissection with associated aneurysm is safe
and effective at midterm follow-up. Aneurysm sac/false lumen pulse pressure measurements demonstrate a sig-
nificant reduction in false lumen endotension, thus ruling out clinically significant persistent retrograde false
lumen perfusion and provide proof of concept for a thoracic endovascular aortic repair-based approach.
Longer-term follow-up is needed to determine the durability of thoracic endovascular aortic repair for this aortic
pathology. (J Thorac Cardiovasc Surg 2011;141:322-7)Approximately 80% to 85% of patients presenting with
type B aortic dissection are managed successfully in the
acute phase with medical therapy.1,2 Unfortunately,
multiple studies3 have demonstrated that 20% to 40% of
these patients will eventually require surgical interventione Department of Surgery, Duke University Medical Center, Durham, NC.
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The Journal of Thoracic and Cardiovascular Surgin long-term follow-up, usually for aneurysmal degenera-
tion of the chronically dissected aorta. Indications for surgi-
cal intervention generally include, in the absence of
symptoms, a descending aortic diameter of 5.5 cm or
more for fusiform aneurysms or 2 cm or more for saccular
aneurysms or interval aortic growth of 5 to 10 mm or more
per year.4 Some, however, have suggested a lower threshold
based on data from E. Stanley Crawford’s series5 demon-
strating that 23% of ruptured chronic type B dissections oc-
curred at an aortic diameter between 5 and 6 cm, as well as
data from the Mt Sinai group in which the median aortic di-
ameter before rupture was 5.4 cm.6 Lower thresholds also
have been proposed for patients with connective tissue
disorders (eg, Loeys–Dietz syndrome).3
Thoracic endovascular aortic repair (TEVAR) is a thera-
peutic advance for the management of acute complicated
(rupture, malperfusion) type B aortic dissection,7 withery c February 2011
Abbreviations and Acronyms
CT ¼ computed tomography
TEVAR ¼ thoracic endovascular aortic repair
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pared with contemporary open repair data.2 However, con-
troversy exists with regard to the use of TEVAR for the
management of chronic type B dissection with aneurysm.8
Critics have cited the fact that the intimal flap becomes
thickened in chronic dissections and does not immediately
reapproximate to the native aortic wall,9 as well as the
fact that distal fenestrations between the true and false lu-
mens become well established over time such that complete
or near-complete false lumen thrombosis is less likely in the
chronic setting.4 For these reasons, the Society of Thoracic
Surgeons Endovascular Surgery Task Force4 gave TEVAR
for chronic type B dissection a class IIb (efficacy not estab-
lished) evidence rating. Thus, the purpose of the present
study was to examine midterm results with TEVAR for
chronic (>2 weeks) type B aortic dissection with associated
aneurysm to better understand the potential role of TEVAR
for this condition.
PATIENTS AND METHODS
Between March 23, 2005 (date of Food and Drug Administration ap-
proval of the first available thoracic device in the United States), and De-
cember 31, 2009, 274 TEVAR procedures were performed at a tertiary
referral university hospital for the treatment of thoracic aortic pathology.
Of these, 51 (18.6%) were for management of chronic dissection of the de-
scending thoracic aorta and form the basis of this report. The indication for
intervention in all cases was aneurysmal degeneration of the chronically
dissected aorta. In all patients, the aneurysmal segment was limited to
the descending thoracic aorta, generally immediately adjacent to the pri-
mary tear, with aortic diameters amenable to distal endograft seal at the
level of the celiac axis. Criteria for repair included rapid enlargement
(>5 mm in 6 months) (n ¼ 7) or absolute size. For fusiform aneurysms,
this included a diameter of 5.5 cm or more (n ¼ 41), whereas for saccular
aneurysms a protrusion of 2 cm or more beyond the aortic wall for the sac-
cular component was considered an indication for treatment in the absence
of symptoms (n ¼ 3).4 The study was approved by the Duke Institutional
Review Board, and the institutional review board waived the need for
individual patient consent.
Devices used were Gore TAG (WL Gore & Associates, Flagstaff, Ariz)
(n ¼ 36; 71%), Zenith TX2 (Cook Medical Incorporated, Bloomington,
Ind) (n ¼ 12; 24%), and Medtronic Talent (Medtronic Inc, Santa Rosa,
Calif) (n ¼ 1; 2%); 2 patients (4%) received more than 1 type of device.
Five patients (10%) required an iliac or infrarenal aortic conduit to allow
safe introduction of the introducer sheath necessary for the procedure.
The left subclavian artery was partially or fully covered in 35 patients
(69%), of whom 6 (17% of those in whom the left subclavian was covered)
underwent adjunctive left carotid-subclavian bypass during the same oper-
ation as endovascular repair. Indications for left carotid-subclavian bypass
were as previously described.10
To definitively evaluate the hypothesis that continued retrograde false
lumen/aneurysm sac pressurization via fenestrations distal to implanted
endografts occurs after TEVAR,4 7 patients (14%) underwent placement
of an EndoSure wireless pressure measurement system (CardioMEMS,The Journal of Thoracic and CaInc, Atlanta, Ga) at the time of TEVAR as previously described.11 The
EndoSure device was intentionally positioned within the false lumen/aneu-
rysm sac adjacent to the primary tear via an existing distal reentry tear that
enabled measurement of potential false lumen pressurization (Figure 1).
The mechanism of the EndoSure sensor has been described.11 Briefly,
alterations in surrounding false lumen/aneurysm sac pressure change the
capacitance and therefore the resonant frequency of the sensor. An external
antenna activates the sensor via a radiofrequency impulse and then receives
the pressure-dependent change via the resonant frequency of the sensor,
which is converted into a real-time pressure measurement.
Preoperative planning of endograft procedures was performed using the
TeraRecon system (TeraRecon Inc, SanMateo, Calif), which allows highly
accurate centerline measurements of flow lumen diameter to assess landing
zones and iliofemoral access vessels. Intravascular ultrasound (Volcano
Corporation, San Diego, Calif) was used in all cases to verify true lumen
access, identify the primary entry tear and areas of distal fenestration,
and evaluate proximal and distal landing zones as previously described.8
All endovascular procedures were performed in the operating room un-
der general anesthesia; adjunctive transesophageal echocardiography was
used routinely. On-line monitoring of spinal cord function with somatosen-
sory and motor evoked potentials was used intraoperatively in elective
cases and when available for urgent/emergency cases (n ¼ 43 cases mon-
itored; 84%) using previously described techniques.12 Cerebrospinal fluid
drainage was used selectively (n ¼ 9; 18%) for previously described
indications.10
Comorbidities were defined using standard definitions. All procedural
outcomes and complications were prospectively recorded. Patient
follow-up included clinical examination, 4-view chest x-ray, and computed
tomography (CT) angiography at 1, 6, and 12 months postoperatively and
annually thereafter. In addition, 3-month follow-up assessment and imag-
ing were obtained in patients with an endoleak identified at 1 month if
the decision for initial endoleak observation was made. False lumen/aneu-
rysm sac pressure tracings were acquired intraoperatively pre- and post-
exclusion of the false lumen, at the time of discharge, and at each
follow-up visit. All follow-up was done at the Duke University Center
for Aortic Surgery. This report includes all data collected through the
patients’ most recent follow-up visit. In addition, the social security death
index was queried (http://ssdi.rootsweb.com/) to confirm all patient deaths.
For those patients dying in follow-up, cause of death was confirmed by
review of medical records or family interview in all cases.
Data were warehoused in an encrypted spreadsheet (Excel 2007, Micro-
soft, Redmond, WA). Descriptive and summary statistics with mean and
standard deviation were calculated. Continuous variables were compared
using the 2-tailed paired Student t test. Statistical analyses were performed
using SAS version 9.13 SP4 (SAS Institute Inc, Cary, NC). Survival anal-
yses were performed using the Kaplan–Meier method. All data are pre-
sented in accordance with the ‘‘Reporting standards for endovascular
aortic aneurysm repair’’ of the Ad Hoc Committee for Standardized
Reporting Practices in Vascular Surgery of The Society for Vascular
Surgery/American Association for Vascular Surgery.13RESULTS
Patient Demographics
Mean aortic diameter was 6.2  1.4 cm. All patients had
a patent false lumen at the time of TEVAR, and the ratio of
true lumen to total aortic caliber was 34%  15%. The in-
terval from initial dissection event to stent graft repair was
a mean of 46.2  53.7 months (range, 2–216 months). Pa-
tient demographics are presented in Table 1. Approximately
half the cohort (n ¼ 24; 47%) had prior aortic surgery, in-
cluding open abdominal aortic aneurysm repair (n ¼ 3;
13%), endovascular aortic repair (n ¼ 2; 8%), openrdiovascular Surgery c Volume 141, Number 2 323
FIGURE 1. Mid-sagittal CT angiogram images of (A) thoracic aorta with chronic type B dissection with aneurysmal dilatation of the false lumen of the
chronically dissected aorta and (B) after TEVAR with false lumen EndoSure (CardioMEMS, Inc, Atlanta, Ga) aneurysm sac/false lumen pulse pressure
sensor in place. True lumen is reestablished with thrombosed false lumen and aneurysm sac/false lumen pulse pressure device. C, Three-dimensional re-
construction of B.
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type A dissection or arch repair (n ¼ 14; 58%). Extent of
aortic coverage by the endograft(s) is presented in
Table 2. Thirteen cases (25%) were urgent (n ¼ 12
[24%] due to acutely symptomatic aneurysms) or emer-
gency (n ¼ 1 [2%] due to hemoptysis).
Procedural (30-Day) Outcomes
The thoracic endografts were deployed in the intended
position in all patients. The median number of stent graft
components per case was 2.0  0.7 (range 1–4); the range
of device diameters used was 26 to 46 mm. Thirty-day/in-
hospital rates of death, stroke, and permanent paraplegia/
paresis were all 0%. Renal failure with new dialysis oc-
curred in 2.0% of patients (n ¼ 1). Two patients (3.9%)
who had preexisting ascending aortic dilation, 1 of whom
had a congenital bicuspid aortic valve, had retrograde acute
type A aortic dissection after implantation of a Zenith
TX2 device, which has proximal barbs for fixation. The first
occurred intraoperatively and was detected via completion
intravascular ultrasound and transesophageal echocardiog-
raphy; immediate repair with mechanical valved conduit
(patient with congenital bicuspid aortic valve) and hemi-TABLE 1. Patient demographics
Median age 57  12 y (range, 30–82)
Female n ¼ 14 (28%)
Hypertension n ¼ 48 (94%)
Active or recent smoker n ¼ 27 (53%)
Diabetes n ¼ 4 (8%)
History of myocardial infarction n ¼ 2 (4%)
History of stroke n ¼ 3 (6%)
COPD n ¼ 9 (18%)
Chronic renal insufficiency
(baseline creatinine  1.5)
n ¼ 12 (24%)
COPD, Chronic obstructive pulmonary disorder.
324 The Journal of Thoracic and Cardiovascular Surgarch replacement was performed, and the patient did well.
The second was delayed, occurring on postoperative day
5 when new-onset chest pain developed in the patient, diag-
nosed by CT angiography (Figure 2). This was likewise an
emergency repair via valve resuspension with ascending
aorta and hemi-arch replacement with good result. Median
postoperative length of stay was 4 days (25th, 75th
percentile ¼ 2, 6 days, respectively).Follow-up Outcomes
Follow-up is 100% complete. Mean duration of follow-
up is 27.0  16.5 months (range, 2–60). Overall actuarial
survival is 77.7% at 60 months, with an aorta-specific actu-
arial survival of 98% during this same time interval
(Figure 3). Of the late deaths, 1 (2.0%) was aortic-related
and the remainder (n¼ 9) were due to comorbid conditions.
The single aortic-related death was a patient who underwent
emergency TEVAR for a symptomatic (pain and hemopty-
sis) 9.3-cm mycotic (Salmonella) descending aneurysm
secondary to chronic type B dissection. She reported persis-
tent dysphagia 1.5 months after endograft placement, and
workup indicated the presence of an aortoesophageal fistula
with the endograft visible on upper endoscopy. She subse-
quently underwent conversion to open repair and died of
complications related to open repair after 30 days.
The previously patent false lumen/aneurysm sac adjacent
to the primary tear was thrombosed in all patients in the se-
ries after TEVAR. Overall aortic diameter decreased from
6.2  1.4 cm preoperatively to 5.0  1.4 cm at latest
follow-up (P¼ .0002). Further, 87% of patients with imag-
ing follow-up beyond 6 months demonstrate complete re-
verse remodeling of the thoracic aorta in the region of
prior aneurysm (Figure 4). The incidence of type I endoleak
at any follow-up visit was 7.8% (n¼ 4); all were seen on the
initial postoperative CT scan and treated successfully withery c February 2011
TABLE 2. Length of aortic coverage by the endograft(s)
Extent of aortic ‘‘pavement’’ No. of patients (%)
Left subclavian artery to T6 19 (37.3%)
Mid thoracic aorta to celiac axis 0 (0%)
Left subclavian artery to celiac axis 32 (62.7%)
FIGURE 3. Actuarial (Kaplan–Meier) overall (solid line) and aorta-
specific (dotted line) survival at 60 months post-endovascular repair for
chronic dissection with aneurysm. Overall survival is 77.7% and aorta-
specific survival is 98% at 60 months.
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months postoperatively; no type I endoleaks were present
at most recent follow-up. There were no type III endoleaks
noted in the study cohort. Two patients (3.9%) underwent
successful endovascular occlusion of type II endoleaks
caused by retrograde flow from the left subclavian artery,
both at 3 months postoperatively. Three patients (5.9%) re-
quired additional distal endografting for metachronous
downstream aortic dilation; reintervention was successful
in all cases. Two patients (3.9%) required late conversion
to open repair, the aforementioned conversion for aortoeso-
phageal fistula and another for continued sac expansion
caused by retrograde filling of the distal false lumen from
a large reentry tear in the visceral segment. Actuarial
freedom from reintervention was 77.3% at 60 months
post-TEVAR (Figure 5).
In the subset of patients (n ¼ 7; 14%) undergoing Endo-
Sure placement in the false lumen, all exhibited a decrease
in aneurysm sac/false lumen pulse pressure, although 1 pa-
tient later manifested an increase to near-systemic pressures
at the 6-month reading because of sensor ‘‘sandwiching’’
between the stent graft and outer aortic false lumen wall
caused by significant reverse aortic remodeling. Of the re-FIGURE 2. CT angiogram demonstrating acute type A aortic dissection
5 days after TEVAR for a chronic type B dissection with associated aneu-
rysm. Note Zenith TX2 stent graft in descending thoracic aorta with com-
pletely thrombosed descending false lumen/aneurysm sac and new
dissection flap in dilated ascending aorta.
The Journal of Thoracic and Camaining 6 patients, the aneurysm sac/false lumen pulse
pressure ratio (ratio of pulse pressure in the false lumen/an-
eurysm sac to systemic pulse pressure) decreased from 52%
 27% at the predischarge measurement to 14%  5% at
the latest follow-up reading (P ¼ .029). The difference
of the means equals a 38% (95% confidence interval,
19–70.4) further reduction in false lumen/aneurysm sac
pressure during follow-up. Similarly, the reduction in aortic
diameter in this subset was statistically significant, with
maximal aortic diameter decreasing from 5.6 0.8 cm pre-
operatively to 4.6  0.9 cm at latest follow-up (P ¼ .0024).DISCUSSION
Controversy persists regarding application of TEVAR for
the management of chronic type B dissection with aneu-
rysm8 mainly because of concerns regarding the thickened
intimal flap that does not readily reapproximate to the native
aortic wall,9 as it does after TEVAR for acute dissection, as
well as the fact that distal fenestrations between the true and
false lumens become more established over time such that
complete or near-complete false lumen thrombosis may
be less likely in the chronic setting.4 For these reasons,
the Society of Thoracic Surgeons Endovascular Surgery
Task Force4 gave TEVAR for chronic type B dissection
a class IIb (efficacy not established) evidence rating.
The present study addresses some of these concerns.
First, overall aortic diameter decreased significantly over
the follow-up period consistent with successful and sus-
tained exclusion of the chronic false lumen/aneurysm sac.
Second, despite the presumed persistence of fenestrations
distal to the endografts, retrograde pressurization of the
false lumen does not occur as evidenced by false lumen/
aneurysm sac pressures that were approximately 14% ofrdiovascular Surgery c Volume 141, Number 2 325
FIGURE 4. Preoperative (A) and 2-year post-TEVAR follow-up (B) 3-dimensional CT angiograms of a chronic type B dissection with associated aneu-
rysm. Note large aneurysm with chronic false lumen in (A) with complete reverse remodeling of entire thoracic aorta in (B) such that no residual aneurysm/
dissection remains in the thoracic aorta.
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patient early in the series who required late open conversion
for continued false lumen/sac enlargement caused by retro-
grade flow from a large visceral segment reentry tear. How-
ever, our experience in treating this disease with TEVAR
has led us to believe that significant retrograde false lumen
pressurization via distal fenestrations to an extent capable of
promoting continued sac expansion does not occur in the
absence of an outflow route, which is typically the left sub-
clavian artery. Two patients in this series underwent late
(3 months) endovascular occlusion procedures for type II
endoleaks from the left subclavian artery with continued
false lumen/aneurysm sac perfusion. In reality, however,
these were not true endoleaks because the flow in the sub-
clavian was actually retrograde away from the false lumenFIGURE 5. Actuarial (Kaplan–Meier) freedom from reintervention is
80% at 12 months and 77.3% at 60 months post-endovascular repair.
326 The Journal of Thoracic and Cardiovascular Surgpotentiated by inflow from downstream fenestrations be-
tween the true and false lumens. In both patients, the false
lumen/aneurysm sac thrombosed and then began to de-
crease in size after the subclavian was occluded. As in 1
of these 2 patients, this retrograde false lumen flow may
be missed if the timing of intravenous contrast and CT im-
age acquisition does not permit adequate opacification of
the false lumen; acquisition of delayed CT images should
be mandatory during follow-up imaging to ensure detection
of continued false lumen flow. In retrospect, we suspect this
to be the case with the earlier patient in this series requiring
open conversion, because his left subclavian artery remains
patent on follow-up imaging after his open conversion
despite presumed left subclavian artery coverage at the in-
dex endograft repair. Finally, consistent with these low false
lumen/sac pressures is the finding of significant reverse
aortic remodeling after depressurization of the chronic false
lumen/aneurysm sac. This reverse remodeling suggests
that, despite the thickened nature of the chronic dissection
flap (3.1  1.8 mm in this series), the flap is able to reap-
proximate to the outer aortic wall with time, generally at
6 months or more follow-up in the present series. Overall,
the findings suggest ‘‘proof of concept’’ for TEVAR for
the treatment of chronic descending dissection with associ-
ated aneurysm. Similar results for TEVAR in chronic de-
scending dissection with aneurysm have been reported by
the Arizona Heart Institute.14
Benchmark data for open repair of chronic type B dissec-
tion in a cohort of n¼ 104 patients were recently published
by the Mt Sinai group.15 The demographics of patients in
that study were similar to the current report with nearly
identical mean age and similar comorbidities. In contrast
with the current report with no 30-day deaths, strokes, or
spinal cord ischemic events, however, they reported 10%
30 day/in-hospital mortality, 6% stroke, and 5% paraplegiaery c February 2011
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with a median postoperative length of stay of 13 days versus
0% and 4 days, respectively, in the current study. Admit-
tedly, however, the extent of aortic disease in the Mt Sinai
study was greater than the current report with 16% of
patients requiring visceral reimplantation because of thora-
coabdominal aneurysmal involvement. Regardless, the cur-
rent report suggests reduced rates of morbidity and
mortality with TEVAR for chronic type B dissection with
aneurysm compared with contemporary open repair data,
similar to findings with acute complicated (rupture, malper-
fusion) type B aortic dissection.7 Although follow-up is
midterm at present, the current study also reports an im-
proved overall survival at 5 years (78% current study vs
68% Mt Sinai series15) after TEVAR versus open repair
for chronic descending dissection. Because the extent of
aortic disease was somewhat greater in the Mt Sinai series,
however, we consider this observation as a preliminary
trend with further study required.
The results of the current study highlight an increased
need for reintervention with a TEVAR-based approach
compared with open repair, although the need for reopera-
tion after open repair increases significantly with duration
of follow-up and was 17% at 10 years in the Mt Sinai se-
ries.15 In the present series, the majority of reinterventions
used endovascular techniques with minimal morbidity and
mortality. Notably, the current data suggest reintervention
is more likely in the first year after TEVAR with the inci-
dence decreasing significantly over the remainder of the
study period (Figure 5).
Our approach is to individualize the use of open repair or
TEVAR based on patient anatomy and comorbid character-
istics. Open repair is clearly the preferred option in patients
with connective tissue disorders, such as Marfan or Loeys–
Dietz syndrome given the poor results of TEVAR in this set-
ting16 and the fact that these patients are typically young
and do well with open repair.17,18 Also, patients with
thoracoabdominal aneurysm will not be treatable with
a TEVAR approach, although ‘‘hybrid’’ repair may be
preferable in some based on comorbid factors.19 Finally,
younger patients with chronic dissection secondary to
malignant hypertension may also be better served with
open repair, although this is not supported by data at present
and the decision regarding TEVAR versus open repair
should ideally be made by a surgical team with expertise
in both techniques, and consideration of institutional results
with each technique should factor heavily into the decision-
making process.
CONCLUSIONS
The current results, consistent with other series published
over the last year,14 suggest a potential benefit for endovas-
cular therapy in chronic descending dissection complicated
by aneurysmal degeneration. Limitations of this studyThe Journal of Thoracic and Cainclude its retrospective nature and reliance on single-
institution data. Further, the duration of follow-up clearly
needs to increase to assess the durability of this therapeutic
modality. By drawing on parallel results from other series
and longer-term data currently available for other TEVAR
indications (eg, aneurysmal disease and acute complicated
type B dissections), it does seem that this technology aug-
ments the surgical armamentarium for the treatment of
chronic descending thoracic aortic dissection.
The authors thank Betty C. Tong, MD, MHS, for statistical
review of this article.
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